Liptruzet: Why Prescribe It?Liptruzet: Why Prescribe It?
Dr. Howard Weintraub discusses the recent approval of Liptruzet, the atorvastatin/ezetimibe combination used to treat elevated LDL-cholesterol levels. Medscape Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Cardiology Expert Interview Source Type: news

Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia
Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder. (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2013 Category: Pharmaceuticals Source Type: news

NSF International Releases Atorvastatin Calcium Reference Standard Kits to Help Manufacturers in India Maintain the Highest Quality Standards
NSF International, an independent global public health organization that develops high quality reference standards, now has Atorvastatin Calcium Reference Standard Kits, which are traceable to official US (USP) and European pharmacopeial (EP) standar… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 5, 2013 Category: Pharmaceuticals Source Type: news

Statin Drugs May Increase Risk Of Diabetes
Certain statins - also known as cholesterol-lowering medications - could increase your risk of developing type 2 diabetes, a new study suggests. The risk was most significant in patients taking atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor), according to the study, published in BMJ. Statins are the most widely prescribed medications for the prevention of cardiovascular events. Generally, these medications are well received, however, a new link to diabetes has been suggested. Previous studies have indicated a 27% elevated risk of diabetes with rosuvastatin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 24, 2013 Category: Consumer Health News Tags: Statins Source Type: news

Risk of Diabetes With Statins Risk of Diabetes With Statins
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes warning over use of statins: People who take the drugs are at increased risk of developing condition
They found a 10 per cent extra risk linked to taking simvastatin - the most commonly prescribed anti-cholesterol drug - which rose to 22 per cent for those taking atorvastatin. (Source: the Mail online | Health)
Source: the Mail online | Health - May 24, 2013 Category: Consumer Health News Source Type: news

Two studies address diabetes risks with statins—one good news, one so-so
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. (Source: theHeart.org)
Source: theHeart.org - May 23, 2013 Category: Cardiology Source Type: news

Liptruzet (Ezetimibe and Atorvastatin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 17, 2013 Category: Drugs & Pharmacology Source Type: news

U.S. spending on medicines fell for first time in 2012
(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Liptruzet Approved By FDA To Cut Cholesterol, Despite Criticism By Cardiologists
Liptruzet, a cholesterol-lowering drug that combines Merck's Zetia (ezetimibe) with atorvastatin (generic version of Pfizer's Lipitor) has been approved by the US FDA (Food and Drug Administration). According to Merck and Co, Liptruzet tablets are for the treatment of high LDL (low-density lipoprotein) cholesterol in patients with primary or mixed hyperlipidemia alongside a special diet when diet alone is not enough. Hyperlipidemia is an excessively high concentration of fats (lipids) in the blood... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 5, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

F.D.A. Approves Merck’s Combination Drug to Reduce Cholesterol
The drug pairs Merck’s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011.     (Source: NYT Health)
Source: NYT Health - May 4, 2013 Category: Consumer Health News Authors: By KATIE THOMAS Tags: Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Food and Drug Administration Zetia (Drug) Cholesterol Lipitor (Drug) Merck & Company Inc MRK NYSE Source Type: news

FDA approves Merck's Liptruzet (atorvastatin/ezetimibe)FDA approves Merck's Liptruzet (atorvastatin/ezetimibe)
The combination, known as Liptruzet, is approved for the treatment of elevated LDL cholesterol levels in patients with primary or mixed hyperlipidemia as an adjunct to dietary changes. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2013 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Merck's Cholesterol Pill Win Is Already Drawing Fire
The Food and Drug Administration just approved Liptruzet, a new cholesterol-lowering pill that combines the generically available ingredient available in Pfizer's Lipitor with Merck's Zetia. Merck has been working to get the combination pill approved for several years -- and one critic is already saying it was a mistake to approve the combination drug. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 3, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

FDA OKs Liptruzet for High LDL
(MedPage Today) -- The FDA approved Liptruzet, a combination of ezetimibe and atorvastatin, for the treatment of hyperlipidemia, drug maker Merck announced today. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 3, 2013 Category: Cardiology Source Type: news